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Background: Severe congenital neutropenia type 4 (SCN4) is an autosomal recessive disorder caused by mutations
in the third subunit of the enzyme glucose-6-phosphatase (G6PC3). Its core features are congenital neutropenia and
a prominent venous skin pattern, and affected individuals have variable birth defects. Oculocutaneous albinism type
4 (OCA4) is caused by autosomal recessive mutations in SLC45A2.
Methods: We report a sister and brother from Newfoundland, Canada with complex phenotypes. The sister was
previously reported by Cullinane et al., 2011. We performed homozygosity mapping, next generation sequencing
and conventional Sanger sequencing to identify mutations that cause the phenotype in this family. We have also
summarized clinical data from 49 previously reported SCN4 cases with overlapping phenotypes and interpret the
medical histories of these siblings in the context of the literature.
Results: The siblings’ phenotype is due in part to a homozygous mutation in G6PC3, [c.829C > T, p.Gln277X]. Their
ages are 38 and 37 years respectively and they are the oldest SCN4 patients published to date. Both presented with
congenital neutropenia and later developed Crohn disease. We suggest that the latter is a previously unrecognized
SCN4 manifestation and that not all affected individuals have an intellectual disability. The sister also has a
homozygous mutation in SLC45A2, which explains her severe oculocutaneous hypopigmentation. Her brother
carried one SLC45A2 mutation and was diagnosed with “partial OCA” in childhood.
Conclusions: This family highlights that apparently novel syndromes can in fact be caused by two known
autosomal recessive disorders.
Keywords: Albinism, Exome sequencing, G6PC3 protein, Inflammatory bowel disease, Oculocutaneous albinism
type 4 (OCA4), Neutropenia, Severe congenital neutropenia type 4 (SCN4), SLC45A2 proteinBackground
Severe congenital neutropenia type 4 (SCN4, OMIM#
612541) is caused by autosomal recessive mutations in
G6PC3 on 17q21.31, which encodes one of the three sub-
units of the enzyme glucose-6-phosphatase. Its features
include congenital neutropenia, a prominent superficial
skin venous pattern and variable congenital malformations* Correspondence: mwoods@mun.ca
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distribution, and reproduction in any medium[1,2]. The syndrome was delineated in 2009 and although
49 other affected individuals have been reported to date,
only 8 others were adults [1-12]. Oculocutaneous albinism
type 4 (OCA4, OMIM# 606574) is a rare form of OCA ex-
cept in Japan. Affected individuals have varying degrees of
ocular and cutaneous hypopigmentation with visual acuity
ranging from 20/30 to 20/400 [13,14]. OCA4 is caused by
autosomal recessive mutations in the solute carrier 45,
member 2 gene (SLC45A2) on 5p13.2 [15]. Here we report
two siblings, a sister and a brother, from Newfoundland,
Canada who were originally thought to have a novel, unde-
scribed syndrome. The sister was previously published bytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dideoxy-based sequencing and next generation sequencing
uncovered that the complex phenotype in this family is
due to G6PC3 and SLC45A2 mutations. We present
the clinical features of the proband and her brother, and
review the phenotypes of the SCN4 patients published
to date. We suggest that the siblings developed several
medical problems, including Crohn disease, which up
until now have not been appreciated as features of SCN4
due to limited information regarding the adult phenotype
of this very rare disorder.Methods
This study was approved by Memorial University’s Human
Research Ethics Authority (Reference# 11.060) and written
informed consent was obtained from the patients.
NC1 and NC2 were the 3rd and 4th of four children
born to second cousin parents who are of Irish descent.
The parents’ first born is a healthy 43-year-old male.
Their second born was a male who had obvious features
of OCA at birth including white hair; he died at age
3 weeks from sepsis. There are two other autosomal re-
cessive disorders (pyridoxine dependent seizures and
beta-galactosidase deficiency) present in more distant
relatives (Figure 1).NC1
This 38-year-old female was diagnosed with severe ocu-
locutaneous albinism at birth. She was born with white
hair, skin which lacked pigmentation and nystagmus.
She has blue irides and her retina is very hypopigmented
with no macular differentiation (Figure 2a). Her visual
acuity is 20/400 (20/200 corrected). With age, sheFigure 1 NC1 and NC2’s pedigree.developed a prominent superficial venous pattern of the
skin of the torso and extremities (Figure 2b and c).
She had E. coli sepsis as a neonate. Neutropenia was
documented at 3 years when she was hospitalized with
laryngotracheobronchitis and pneumonia. By 5 years,
she developed chronic bacterial and herpetic gingivosto-
matitis. During childhood she had recurrent otitis media,
skin boils and urinary tract infections (her ureters were
reimplanted at 12 months). Through later childhood she
received trimethoprim/sulfamethoxazole prophylaxis.
Bone marrow biopsy at 16 years showed hyperplasia of
granulocyte precursors with maturation arrest. At
21 years, she started receiving weekly recombinant
human granulocyte colony stimulating factor (G-CSF)
and has been compliant with therapy. Current dose is
Neupogen (Amgen, Thousand Oaks, CA) 1.5 ug every
2nd day. This improved her absolute neutrophil count
(ANC) and decreased the frequency and severity of her
infections.
At 12 years, intermittent thrombocytopenia was docu-
mented and platelet aggregation studies were abnormal,
with decreased response to mini-dose ADP and no re-
sponse to adrenaline. Her platelet counts have been as
low as 25 × 109/L (normal 130-400), with no bleeding
complications. Electron microscopy of platelets showed
that dense bodies were present (excluding the diagnosis
of Hermansky-Pudlak syndrome) [17]. Intermittent lym-
phopenia was identified at age 27 years.
At 7 years, NC1 developed recurrent abdominal pain.
At 16 ½ years, she was diagnosed with Crohn disease
(CD) and at 17 years had a right hemicolectomy which
showed typical CD histology. A stricture developed at
the anastamosis site and at 34 an ileostomy was created.
Within 12 months, she developed renal insufficiency
Figure 2 a) NC1’s retina showing severe hypopigmentation with absent macular differentiation; b, c) NC1’s right arm and left leg
showing that she has a prominent superficial venous pattern of the extremities; d, e) NC1 at age 38 years. She has white hair with a
yellowish hue, short narrow palpebral fissures, midface hypoplasia, full lips and prognathism. Note the visible vein in her left temporal area;
f) NC2’s iris showing partial iris transillumination g); NC2’s retina showing reduced retinal pigmentation; h) NC2 at age 8 years; i) NC1 at
age 10 years.
Fernandez et al. BMC Medical Genetics 2012, 13:111 Page 3 of 9
http://www.biomedcentral.com/1471-2350/13/111
Fernandez et al. BMC Medical Genetics 2012, 13:111 Page 4 of 9
http://www.biomedcentral.com/1471-2350/13/111attributed to repeated pre-renal insults from high out-
put through her ileostomy, and she is about to start
hemodialysis.
At age 32, mild splenomegaly was identified and an
atrial septal defect (ASD) was repaired. At 35, she was
diagnosed with mild pulmonic hypertension which has
been stable by echocardiogram with a right ventricular
systolic pressure of 50 millimeters of mercury.
She completed high school and several years of post-
secondary education. She is employed as an office ad-
ministrator. She went through puberty normally and
started menstruating at 12 years. Her periods were regu-
lar until she developed renal insufficiency.
On examination at 38 years, NC1’s height was
153.5 cm (5-10th centile), weight was 68.3 kg (75-90th
centile) and head circumference was 55 cm (mean). Her
hair was white with a yellowish hue and she had silvery
white eyebrows and eyelashes. She had pale blue irides
with short, narrow palpebral fissures and midface hypo-
plasia. Her lips were full and she had prognathism
(Figure 2d,e). Her pupils constricted poorly to light and
she had horizontal and vertical nystagmus. Her skin was
very fair with unusually visible veins of the torso and ex-
tremities (Figure 2b,c) She had varicose veins of the
lower legs and thighs. Some clinical information on NC1
was previously reported [16].
NC2
This male sibling was 2 years younger than the proband
(NC1) and also had congenital neutropenia with recur-
rent bacterial and herpetic infections. He was prescribed
G-CSF at 20 years, but was less compliant with the the-
rapy than his sister. As an adult, intermittent lymphope-
nia and thrombocytopenia were documented, and he
also had a platelet aggregation disorder with no clinical
bleeding problems. He died of infective endocarditis at
37 years.
His ureters were reimplanted at 2 years, a secundum
ASD was repaired at 5 years and he had several surgeries
for bilateral cryptorchidism. Glasses were prescribed at
6 years and at 8 years, he was diagnosed with a mild
form of OCA because of partial iris transillumination
and retinal hypopigmentation (Figure 2f,g). His hair was
light brown and he had fair skin which burned easily
with sun exposure. His irides were blue. He did not have
nystagmus and visual acuity was 20/30. He had the same
facial dysmorphism as his sister (Figure 2 h,i).
He went through puberty normally. Height at 14 years
was 142 cm (10th centile). At 14 years, mitral valve pro-
lapse was identified. At 15 years, he had a right hemico-
lectomy for an inflammatory obstruction and was
diagnosed with CD. He failed medical management and
at 33 had a subtotal colectomy with an ileorectal anasta-
mosis. Because of short bowel syndrome, a leftsubclavian portacath was inserted, but was removed be-
cause of line infections. At 30 years, he developed mild
hepatosplenomegaly. He had several years of post-
secondary education and was employed as a medical la-
boratory technologist.
Several weeks before his death, NC2 presented with a
two-month history of fever and dyspnea, and was diag-
nosed with renal insufficiency, severe mitral and aortic
insufficiency and infective endocarditis. He died of mul-
tisystem organ failure.
Molecular genetics
Both siblings were genotyped for 865,644 SNPs using
the Affymetrix 6.0 array. HomozygosityMapper [18] was
used to identify regions of shared homozygosity between
NC1 and NC2. A block length of 1000 was used and
identified three regions of interest.
Sanger sequencing was performed for candidate genes
in the chromosomal region identified by Homozygosity-
Mapper on chromosome 17q12-21. Primer sequences
and conditions are available upon request for G6PC3.
PCR products were sequenced on an ABI Sequencer
3130XL and data was analyzed using Sequencing Ana-
lysis 5.2 and Sequencher 4.9.
Exome sequencing was performed using Agilent Sure-
Select Human All Exon v3 kit (Agilent Technologies)
and paired end sequenced on a SOLiD 4 instrument
(Life Technologies) following the manufacturers’ proto-
cols. Raw sequence data was mapped to the reference
human genome hg19 (downloaded from UCSC Genome
Browser) using BFAST [19]. The Genome Analysis Tool
Kit (GATK) version 1.05506 (Broad Institute) was used
to remove PCR duplicates and refined the alignments,
before SNP and indel calling were performed with
GATK default parameters. Variant annotation was car-
ried out using SIFT 4.0.3 [20]. QD and SB are para-
meters of the GATK pipeline commonly used to reduce
the variant search space by eliminating, respectively,
false positive calls and variants sequenced from one dir-
ection only. Only novel SNPs and indels that had quality
by depth (QD) ≥ 10, strand bias (SB) ≤ -0.01, and were in
coding regions causing non-synonymous changes, amino
acid deletions or frameshifts were prioritized as potential
candidates.
Results
Three homozygous regions common to both siblings
were identified, the largest of which was a 17.9 megabase
(Mb) region on 17q12-21.33 which contains more than
425 genes. Using a candidate gene approach, both sib-
lings were found to have a homozygous nonsense muta-
tion of the SCN4 gene, G6PC3 (17q21.31). This mutation
[c.829C > T, p.Gln277X] was previously reported in a
French SCN4 patient [2].
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siblings’ phenotype (i.e. the OCA), exome sequencing
was performed on the proband. As we were analyzing
the data, the proband (NC1) was published by Cullinane
and colleagues [16]. These authors also used homozy-
gosity mapping and exome sequencing approach to
identify the homozygous SCN4 mutation, as well as a
homozygous mutation in the OCA4 gene, SLC45A2 on
chromosome 5p13.2. Our exome data showed the same
OCA4 mutation [c.986delC, p.T329RfsX68], which we
confirmed by Sanger sequencing as homozygous in the
proband and heterozygous in her brother. The c.986delC
variant was previously reported as a mutation in five
German OCA4 patients [14].
Discussion
Evaluation of the siblings in childhood suggested they
had the same provisionally unique autosomal recessive
disorder. Given their ocular and skin hypopigmentation,
immune problems and CD, the best unifying diagnosis
was considered to be a variant of Hermansky-Pudlak
syndrome, although the proband’s platelet electron mi-
croscopy results made this diagnosis less likely. Un-
doubtedly the pediatric diagnosis of “mild albinism” in
the proband’s brother was influenced by the fact that the
siblings had several shared medical features (ASD, neu-
tropenia, abnormal platelets) coupled with the fact that
NC1 had classic OCA. Both siblings have a homozygous
stop mutation in G6PC3 and SCN4 explains many of
their medical problems. NC1 also has a homozygous
SLC45A2 frameshift mutation, whereas her brother
(NC2) carried only one OCA4 mutation. The OCA4
gene is not located within one of the three homozygous
blocks shared between the siblings, but is within one of
NC1’s identical by descent (IBD) regions. Following
identification of the siblings’ homozygous SCN4 muta-
tion, if we had considered variants from NC1’s exome
analysis located only within regions of homozygosity
shared between the sibs, the SLC45A2 mutation would
have been missed. Thus, this analysis underscores the dif-
ficulties related to correctly delineating medical syn-
dromes and identifying the responsible gene when more
than one recessive disorder segregates in a family. Al-
though we have not excluded the possibility of digenic in-
heritance, we suggest that NC2’s mild hypopigmentation
was a heterozygote manifestation; this has not to our
knowledge been previously reported in any of the reces-
sive forms of OCA.
Apart from NC1 and NC2, 49 other individuals with
SCN4 have been described in the literature, most of
whom were children [1-12]. Including NC1 and NC2, 10
adults have been reported with an age range of 20-
38 years [1,3,6,8]; NC1 (38 years old) and NC2 (who
died at 37) are the oldest individuals with SCN4published to date. The clinical features of all 51 affected
individuals are summarized in Table 1. The most com-
mon birth defect is ASD, present in 38 of 51 (74.5%) indi-
viduals, followed by cryptorchidism in 52% of males. The
Newfoundland siblings developed thrombocytopenia
which has been reported in 27 other patients [1-7,10-12],
suggesting that this is also a key SCN4 hematologic
manifestation. NC2 was diagnosed with mitral valve pro-
lapse in childhood and likely developed progressive mi-
tral valve disease. Cardiac valve abnormalities were
present in 11/49 previously reported patients, including
six cases with mitral and/or tricuspid insufficiency, two
with pulmonic stenosis and one with mitral stenosis
[1,2,6-8,10,11]. This suggests that valvular abnormalities
are part of the cardiac phenotype.
Banka and colleagues [1] speculated that individuals
with SCN4 might have recognizable dysmorphic facial
features and earlier this year Boztug et al. [7] reported
variable facial dysmorphology in 12/16 patients. Only
two other photographs of affected individuals have been
published [1,7]. One of these is a 26-year-old male who
had midface hypoplasia, full lips and prognathism [1],
features also present in NC1 and NC2, suggesting that
individuals with SCN4 may have a recognizable facial
gestalt.
Of the eight previously reported adults with SCN4,
one 24-year-old female was developmentally delayed [6]
and another three adults had an intellectual disability
(ID) [1] (Table 1). This led Banka et al. [1] to
hypothesize that ID is part of the syndrome. The three
individuals with ID that they described belonged to a
large consanguineous family and may have had a second
recessive disorder. NC1 and NC2 successfully completed
post-secondary education suggesting that ID is a variable
SCN4 manifestation or that it is not part of the syn-
drome. Although neither NC1 nor NC2 had failure to
thrive or growth failure, these are probably variable fea-
tures. Failure to thrive has been reported in 22/49
(44.9%) of patients [1-3,5-10] (Table 1). Moreover six of
eight previously reported adolescents/adults had short
stature [1,6-8] (Table 1).
G6PC3 is a ubiquitously expressed gene which
encodes a subunit of glucose-6-phosphatase [21,22]. This
enzyme catalyzes the final step in the glycogenolytic and
gluconeogenic pathways, the conversion of glucose-6-
phophate to glucose [23]. Glycogen Storage Disease Ia
(GSDIa, OMIM# 232200) is caused by autosomal reces-
sive mutations in G6PC1, which encodes one of the
other subunits of glucose-6-phosphatase. Banka et al. [1]
suggested that SCN4 patients might develop some of the
same long-term complications as individuals with GSDIa
including pulmonary hypertension, renal failure and
platelet dysfunction. Our patients both developed end
stage renal disease in the 3rd decade. As adolescents,
Table 1 Summary of clinical features of 51 patients with severe congenital neutropenia type 4 (SCN4) including the two adult siblings described in this report
FEATURES This
report
Banka,
Chervinsky
et al,
2010A
Boztug
et al,
2009
Arostegui
et al,
2009
Xia
et al,
2009
Banka,
Newman
et al,
2010B
Germes-
hausen
et al,
2010
Boztug,
Rosenberg
et al,
2012
Smith
et al,
2012
Alizadeh
et al.,
2011
McDerm-ott
et al,
2010
Gatti
et al,
2011
Milá
et al.,
2011
Total
(n=2) (n=4) (n=12) (n=1) (n=2) (n=2) (n=2) (n=16) (n=4)C (n=2) (n=2D) (n=1) (n=1) (n=51)
Cardiac
Atrial septal defect 2/2 2/4 7/12 1/1 2/2E 2/2 2/2 15/16 1/4 2/2 1/2 1/1 0/1 38/51
PDA 0/2 2/4 1/12 0/1 0/2 0/2 0/2 2/16 0/4 0/2 0/2 0/1 0/1 5/51
Valvular defects 1/2 1/4F 2/12G 0/1 0/2 0/2 1/2H 4/16I 1/4J 0/2 1/2K 1/1L 0/1 12/51
Hypoplastic left heart 0/2 0/4 0/12 0/1 0/2 0/2 0/2 1/16 0/4 0/2 0/2 0/1 0/1 1/51
Other 0/2 0/4 0/12 0/1 1/2E 0/2 0/2 0/16 1/4J 0/2 1/2K 0/1 1/1M 4/51
Pulmonary
Pulmonary hypertension 1/2 1/4N 0/12 0/1 0/2 2/2O 0/2 0/16 0/4 0/2 1/2K 0/1 0/1 5/51
Other 0/2 0/4 1/12P 0/1 0/2 0/2 0/2 0/16 0/4 0/2 0/2 0/1 0/1 1/51
Birth defects
Cryptorchidism 1/1 1/2 4/6 1/1 0/2Q 1/1 1/1 5/11 0/3 0/2 1/1 1/1 1/1 17/33
Other genital 0/2 0/4 1/12R 0/1 0/2 0/2 1/2S 4/16T 0/4 0/2 0/2 0/1 0/1 6/51
Renal/ureters 1/2 1/4U 1/12V 0/1 0/2 0/2 0/2 6/16 0/4 1/2 0/2 0/1 0/1 10/51
Cleft palate 0/2 0/4 1/12 0/1 0/2 0/2 0/2 0/16 0/4 0/2 0/2 0/1 0/1 1/51
Other 0/2 1/4W 0/12 0/1 0/2 2/2X 0/2 4/16Y 0/4 0/2 0/2 0/1 0/1 7/51
Features in infancy/childhood
Prominent skin venous
pattern
2/2 4/4 10/12 1/1 NA NA 2/2 14/16 0/4 1/2 2/2 1/1 1/1 38/47
Poor growth/FTT 0/2 4/4 3/12 1/1 NA 2/2 1/2 7/16 1/4 1/2 2/2 0/1 0/1 22/49
Microcephaly (relative) 0/2 0/4 2/12 0/1 NA 0/2 1/2 0/16 0/4 0/2 2/2 0/1 0/1 5/49
DD/LD 0/2 4/4 NA 1/1 NA NA 1/2 2/16 0/4 NA 0/2 0/1 0/1 8/33
SNHL or hearing loss 0/2 0/4 2/12 0/1 NA NA 1/2 2/16 0/4 0/2 2/2 1/1 0/1 8/47
Features in adolescence /adulthood
Varicose veins 2/2 3/3 NA NA NA NA NA 0/5 0/2 NA NA NA NA 5/12
Delayed puberty 0/2 2/3 NA NA NA NA 1/2Z 2/5 0/2 NA NA NA NA 5/14
Intellectual disability 0/2 3/3 NA NA NA NA 1/2 0/5 0/2 NA NA NA NA 4/14
Short stature 0/2 3/3 NA NA NA NA 1/2 1/1 1/2 NA NA NA NA 6/10
Crohn diseaseAA 2/2 0/3 NA 0/1 NA NA 0/2 NA 2/3 NA NABB NA NA 4/11
Fernandez
et
al.BM
C
M
edicalG
enetics
2012,13:111
Page
6
of
9
http://w
w
w
.biom
edcentral.com
/1471-2350/13/111
Table 1 Summary of clinical features of 51 patients with severe congenital neutropenia type 4 (SCN4) including the two adult siblings described in this report
(Continued)
Features in childhood or adulthood
Growth Hormone
deficiency
0/2 0/4 0/12 0/1 0/2 0/2 0/2 2/16 0/4 0/2 0/2 0/1 0/1 2/51
Hepatomegaly &/or
splenomegaly
2/2 NA 3/12 0/1 0/2 1/2 0/2 2/16 1/4 0/2 0/2 0/1 0/1 9/47
Thrombocytopenia 2/2 1/3 5/12 1/1 2/2 2/2 2/2 10/16 0/4 0/2 2/2 1/1 1/1 29/50
Patients > age 18 years 1M (37yr) 1M (26 yr) 0/12 1M (22yr) Ages not given 0/2 1 M (20yr) 0/16 2MCC (30yr, 23 yr) 0/2 0/2 0/1 0/1 10/51
1 F (38yr) 2F (29 yr, 25 yr) 1F (24yr)
ASD atrial septal defect, PDA patent ductus arteriosus, FTT failure to thrive, DD developmental delay, LD learning disability, SNHL sensorineural hearing loss, yr age in years, M male, F female.
A. Banka S, Chervinsky E et al., 2010: One large consanguineous Israeli (Arab-Muslim) kindred.
B. Banka S, Newman W et al, 2010: 2 siblings born to non-consanguineous Turkish parents who were initially reported as Dursen syndrome. Both died at 18 months.
C. Smith et al. report four probands and briefly mention one additional patient (an affected sister of the 1st proband; few clinical details are provided).
D. a brother and sister (ages 13 years and 9 years respectively).
E. One patient had an ASD and a coronary aneurysm.
F. Pulmonary valve stenosis.
G. One patient with pulmonary stenosis, another with mitral insufficiency.
H. A 24 year old female with mild mitral and tricuspid insufficiency.
I. Two patients with bicuspid aortic valve (11 yr and 18 yr), one with mitral and tricuspid regurgitation (11 yr), one with mild tricuspid regurgitation (11 yr).
J. One patient with tricuspid insufficiency and patent foramen ovale (11 yrs).
K. At age 13 years, the brother had congenital mitral valve thickening, asmall patent foramen ovale and mild pulmonary hypertension.
L. 10 year old male with tricuspid and mitral regurgitation and an unrepaired secundum ASD.
M. 11 year old male with cardiomyopathy.
N. Patient developed pulmonary hypertension shortly after birth.
O. Both siblings developed pulmonary hypertension, diagnosed in the first few months of life.
P. One patient with a pulmonary venous malformation.
Q. Neither the age nor the sex of the patients was specified.
R. One male with cryptorchidism and genital dysplasia.
S. One male with cryptorchidism and genital dysplasia.
T. One female with discontinous labia majora and minora, two males with micropenis, one male with ambiguous genitalia.
U. Patient had unilateral renal agenesis and hydronephrosis of the remaining kidney.
V. Patient had a urachal fistula.
W. One female with bilateral keratoconus.
X. Both siblings had thymic hypoplasia and a pectus carinatum deformity.
Y. Two cases of cutis laxa: a Persian female and a Turkish male (both with consanguineous parents); two cases with ptosis.
Z. Hypogonadotrophic hypogonadism.
AA. Denominator is number of patients older than age 18 years.
BB. Both siblings had gastrointestinal malabsorption.
CC. The adult affected sister of the first proband was not included; her exact age was not specified and the clinical description was very brief.
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and a platelet aggregation defect. NC1 developed pul-
monary hypertension in her mid-30’s and is the 5th
reported SCN4 patient who developed this complication
[1,5,10] (Table 1). Collectively, these findings support
the hypothesis that long-term complications may be
shared between individuals with mutations in G6PC3
and G6PC1.
NC1 and NC2 developed severe adolescent-onset
Crohn disease, and we hypothesize that the siblings’ CD
is SCN4-related. Firstly, 15 SCN4 patients older than age
12 years have been published including two others with
CD [8], a 30-year-old Pakistani male who was not
treated with G-CSF until at least age 9 years and his
sister, about whom few other clinical details were pro-
vided. Secondly, Glycogen Storage Disease Ib (GSDIb,
OMIM#232220) is due to autosomal recessive muta-
tions in SLC37A4 which encodes a protein that trans-
ports glucose-6-phosphatase from the cytosol to the
endoplasmic reticulum where the enzyme acts [24].
Some individuals with GSD1b develop neutropenia
and there is a high incidence of CD in GSD1b
patients, but only in the neutropenic subset [25,26].
In 2002, Dieckgraefe et al. [26] ascertained 36 North
American GSD1b patients of whom 28% (all with
neutropenia) had CD with an average diagnosis age of
8-9 years. The gastrointestinal symptoms in all 10
patients improved with G-CSF. Finally, Crohn disease
has also been associated with other neutrophil-centered
immunodeficiency syndromes including chronic granu-
lomatous disease [27], Chediak-Higashi syndrome [28],
leukocyte adhesion deficiency [29], cyclic neutropenia
[30] and autoimmune neutropenia [31]. In 2000, Korze-
nik and Dieckgraefe [32] hypothesized that defects in
innate immunity predispose some individuals to CD.
They suggested that although standard CD therapy
dampens the chronic recruitment of B and T-cells to
the gastrointestinal mucosa, in some CD patients an
earlier step is failure of adequate mucosal neutrophil
function in the face of a microbial challenge. If this
pathophysiologic mechanism is correct, then using G-
CSF to normalize the ANC of patients with CD and a
neutrophil deficiency syndrome should improve the
course of their CD.Conclusions
In summary, our findings expand the natural history of
SCN4. Additional reports are needed to determine if
other older SCN4 patients have developed Crohn di-
sease, other GSD1a/b complications or valvular heart
disease. If CD is indeed a feature of SCN4, then early
treatment with G-CSF is likely to ameliorate its course
and presymptomatic treatment could prevent itsoccurrence. Meanwhile we suggest monitoring SCN4
patients for valvular heart disease and pulmonary hyper-
tension with serial echocardiograms.
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